Panel Disdussion

More documents

Recommendations

Info

3rd International Congress 3rd International of Nuclear Congress Medicine of Nuclear & 15th Medicine Iranian Annual & 15th Iranian Congress Annual of Nuclear Congress Medicine of Nuclear Medicine Shahid Beheshti Shahid Beheshti University University of Medical Sciences of Medical 19-21 Sciences May 201119-21 May 2011 Production of Os191/Ir191m generator by Tehran Research Reactor Leila Moghaddam-Banaem 1 , Amir Reza Jalilian 1 , Nafiseh Salek 2 , Mina Jamreh 2 , Mojtaba Shamsaee 2 1 Radiopharmaceutical Research and Development Lab (RRDL) 2 Faculty of Nuclear Engineering and Physics-AmirKabir Technical University In this research production of 191Os/191mIr generator was investigated. 191Osmium is a parent radionuclide with 15.4d half-life and 191mIridium is daughter radionuclide with 4.96s half-life. It decays by isometric transition to stable 191Ir, emitting a 129-keV gamma photon. In addition, iridium x-rays at about 65 keV are emitted, as a result of internal conversion, from the 129-keV excited state. The half-life of 191Os (15.4 days) is sufficiently long to facilitate transportation, generator construction, quality control, and clinical use. 191mIr is recently has been used as an angiography radionuclide. One major use of this technique is in the evaluation of children with congenital heart disease. The information obtained with radio-angiography is of importance in the diagnosis and management of these patients and, at times, can take the place of a cardiac catheterization. In this work, 191Os-hexachloro-osmate was obtained by thermal neutron flux (4—1013 n.cm-2.s-1) of natural osmium oxide sample followed by fusion with KOH and KNO3 in acidic media. One of the important radionuclide impurities is 192Ir that produced with 191Os in reactor. Separation this impurity from 191Os is developed by a new performance in this research and the total recovery yield of 191Os is about %99 and the total time required for completion the procedure is about 2h. This method improved the yield and the time of performance in comparison with the published literatures. Then 191Os is loaded on an anion-exchange column and 191mIr eluted with normal saline. Each elution is 1 ml of 0.9% saline at pH 1. The yield of generator was assessed for two weeks. 191mIr yield is 8 to 11% and 191Os breakthrough is 0.001 to 0.005%. Keywords: Radiopharmaceutical, Gnerator 191Os/191Ir 160
3rd International Congress of of Nuclear Medicine & & 15th 15th Iranian Annual Annual Congress of Congress of Nuclear Medicine Shahid Beheshti Shahid Beheshti University University of Medical of Medical Sciences Sciences 19-21 19-21 May May 2011 Preparation and evaluation of 166Ho-DTPA for medical applications H. Salehi, M. Gourani, H. Farahani, M. Zoghi, M. Mazidi, S. Shaybani Radioisotope research Group, Science & Technology Nuclear Center (NSTRI) Atomic Energy Organization of IRAN (AEOI) Introduction: Radiopharmaceuticals are now increasingly used for therapy of cancer, palliation of pain caused due to bone metastasis and for the treatment of rheumatoid arthritis. 166Ho, with its favorable radiation characteristics of t1/2 26.8 h and β 1.85 and 1.75 MeV is decayed to stable daughter. It also emits an 80.5 Kev gamma-ray (6.2%) and thus is imaginable by conventional techniques. Purposes: Irradiating 165Ho(n,γ)166Ho 2- Labeling 166HoCl3- DTPA(diethylentriaminepentaacetic acid). Investigation Methods: Holmium oxide (Ho2O3, purity >99.9%, 1- 3 mg target mass) was irradiated in a thermal neutron flux 5—1013 n.cm-2.s-1 in the TRR reactor. Irradiated target is dissolved in 20% HCl, evaporated to dryness. 166Ho should be labeled by DTPA kit as a complex (DTPA: 166HoCl3) with a same molecular weight (1:1) and pH~ 7-8 at room temperature in 30 min. Results: The purity of radionuclide was checked by a multichannel analyzer coupled with HPGe detector and measured in curimeter dose calibrator. The radiochemical purity of the DTPA:166HoCl3 was determined by paper chromatography and 0.9% saline as solvent. Radiochemical purity of the DTPA:166HoCl3 was 99 %. Gamma spectrometry of the 166Ho didn't show gamma peaks for any other radionuclide other than 166Ho. CONCLUTION: Results of this investigation indicate that 166HoCl3:DTPA kit proposed as a suitable choice for the endovascular radionuclide therapy (EVRT) technique of liquid filled, low pressure balloon angioplasty. In a study using mice >85% of the injected dose was cleared into the urine within 30 min post-injection, with insignificant retention in any major tissues. The studies show that the 166Ho-DTPA complex could be an alternative to the more expensive and difficult to access 188Re based products for EVRT, and provide adequate uniform radiation dose for the arterial vessel wall under treatment. Keywords: ho-166 DTPA Irradiation angioplasty 161
Page 1 and 2:
3rd International Congress of Nucle
Page 3 and 4:
Page 5 and 6:
Page 7 and 8:
3rd International Congress of of Nu
Page 9 and 10:
Page 11 and 12:
Page 13 and 14:
Page 15 and 16:
Page 17 and 18:
Page 19 and 20:
Page 21 and 22:
Page 23 and 24:
Page 25 and 26:
Page 27 and 28:
Page 29 and 30:
Page 31 and 32:
Page 33 and 34:
Page 35 and 36:
Page 37 and 38:
Page 39 and 40:
Page 41 and 42:
Page 43 and 44:
Page 45 and 46:
Page 47 and 48:
Page 49 and 50:
Page 51 and 52:
Page 53 and 54:
Page 55 and 56:
Page 57 and 58:
Page 59 and 60:
Page 61 and 62:
Page 63 and 64:
Page 65 and 66:
Page 67 and 68:
Page 69 and 70:
Page 71 and 72:
Page 73 and 74:
Page 75 and 76:
Page 77 and 78:
Page 79 and 80:
Page 81 and 82:
Page 83 and 84:
Page 85 and 86:
Page 87 and 88:
Page 89 and 90:
Page 91 and 92:
Page 93 and 94:
Page 95 and 96:
Page 97 and 98:
Page 99 and 100:
Page 101 and 102:
Page 103 and 104:
Page 105 and 106:
Page 107 and 108:
Page 109 and 110: 3rd International Congress of of Nu
Page 159: 3rd International Congress of of Nu
show all

Panel Disdussion

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?